An FDA expert panel recommended approval of Mylan's MYL-14010, a biosimilar candidate for Genentech's trastuzumab, putting it on track to become the first approved biosimilar for cancer. Experts predict that biosimilars will lead to lower drug prices, but caution that the savings won't be as dramatic as that seen with generics.
from Cancer via ola Kala on Inoreader http://ift.tt/2wtYlaR
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου